Clinical efficacy and safety of SM-4300, a newly developed human immunoglobulin, have been studied in 7 episodes of severe infections complicated with advanced cancer. Clinical effect of SM-4300 was good in 1 case, fair in 5 and poor in 1. The efficacy rate was summarized as 14.35%, and the rate including fair response was 85.7%. No subjective and objective clinical side effect was observed and abnormal laboratory findings were not noted. In conclusion, combination therapy with SM-4300 and antibiotics was considered to be safe and effective against the patients with severe infections complicated with advanced cancer.